INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONS
Bibliographic record
Abstract
Objectives & Background Dabigatran, an oral thrombin inhibitor, is widely used for stroke prevention in atrial fibrillation. Idarucizumab, a monoclonal antibody fragment directed against dabigatran, demonstrated immediate, complete and sustained reversal of the anticoagulant effect of dabigatran, without procoagulant activity, in animal models and human volunteers. Aims To examine the efficacy and safety of idarucizumab to rapidly reverse the anticoagulation effects of dabigatran in critical clinical situations. Methods RE-VERSE AD is an ongoing multinational, open-label, single cohort study with a target size of up to 300 patients. It is designed to study the reversal of dabigatran's anticoagulant effect by 5 g idarucizumab given as two 2.5 g IV bolus infusions, in patients who experience life-threatening or uncontrollable bleeding (Group A) or who require emergency surgery or invasive procedure (Group B). The primary endpoint is the maximum reversal of the anticoagulant effect of dabigatran, based on central laboratory determination of the dilute thrombin time or ecarin clot time up to 4 hours after idarucizumab administration. Drug levels and other measures of dabigatran activity are also determined. Clinical outcomes, including cessation of bleeding, thrombotic events, and other safety measures, are assessed. Results In the first 90 patients, idarucizumab normalized clotting tests in at least 90% of patients, an effect evident at the first measurement. There was one thrombotic event within 72 hours of idarucizumab administration in a patient whose anticoagulant therapy had not been restarted. Conclusion Idarucizumab is a promising specific reversal agent that rapidly and safely reverses dabigatran's anticoagulant effects within minutes in emergency situations that reflect real world clinical practice.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.012 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".